
                      Download 8-K Special Filing Report
                    
                    
                      Original filing index
                    

Announcement: ICAD 8-K Special Filing

Analyst Summary:

iCAD, a global medical technology company providing cancer detection and therapy solutions, announced its financial results for the fourth quarter and year that ended on December 31,...

$ICAD reports Q4 revenue of $6.5M; considers strategic options for Therapy line

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/749660/000119312523069167/d472491d8k.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/749660/000119312523069167/0001193125-23-069167-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Form 8-K - Current report - Item 2.02 Item 9.01

Icad Inc

Analyst Summary:

iCAD, a global medical technology company providing cancer detection and therapy solutions, announced its financial results for the fourth quarter and year that ended on December 31, 2022, and stated that it is considering strategic options for its Therapy business line. The company will host a conference call on March 28, 2023, to discuss the full report. Based on preliminary, unaudited financial information, the company estimates total revenue for the fourth quarter ended December 31, 2022, to be $6.5 million. iCAD is making efforts to align its cost base with changes in revenue. The company's final consolidated financial results for the three months ended December 31, 2021, may differ materially from the estimates and interim balances provided in the current press release. The company has also engaged investment bankers to explore strategic options for its Therapy business line.